Is the price fair?
What HAE's price assumes
Haemonetics Corporation trades at 50.2× earnings against 30.9× for the median Medical Devices name, more expensive than its own group.
50.2
Trailing P/E · Medical Devices median 30.9 · 1.63× the median: the market pays up for this one
- Price / sales
- 1.83
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.4%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +0.47%
Growth the price implies · The price pays for +0.47% free cash flow growth a year for a decade; the business has delivered +47% a year over the last three.
Details›
- Price / book2026-Q1
- 3.07
- EV / EBIT2026-Q1
- 21.9
- EV / sales2026-Q1
- 2.58
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $260M
- Market capitalisation
- $3.53B
- 3-year revenue growth
- +4.5%
- 3-year free cash flow growth
- +47%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 21.3× today against a 54.1× median |
| 52-week range | $47.67 – $108.76 |
| Today | $102.86 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.